Published in J Natl Cancer Inst on August 19, 2013
Re: Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA. J Natl Cancer Inst (2014) 1.45
Re: CYP2D6 genotyping and the use of tamoxifen in breast cancer. J Natl Cancer Inst (2014) 1.08
Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen. Clin Pharmacokinet (2015) 0.87
CYP2D6 genotyping and tamoxifen in the treatment of post-menopausal breast cancer. Br J Clin Pharmacol (2014) 0.81
CYP2D6 genotype and tamoxifen: considerations for proper nonprospective studies. Clin Pharmacol Ther (2014) 0.78
Breast cancer recurrence in relation to antidepressant use. Cancer Causes Control (2015) 0.77
CYP2D6 genotyping and tamoxifen in the treatment of post-menopausal breast cancer - a reply. Br J Clin Pharmacol (2014) 0.76
Response. J Natl Cancer Inst (2014) 0.75
Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA. J Natl Cancer Inst (2013) 3.35
Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol (2002) 6.51
Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med (2004) 4.84
Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA (2005) 3.43
Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res (2012) 3.14
Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am (2003) 2.82
DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol (2009) 2.23
Dexmedetomidine use in a pediatric cardiac intensive care unit: can we use it in infants after cardiac surgery? Pediatr Crit Care Med (2009) 1.96
The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res (2010) 1.85
Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res (2006) 1.69
Dexmedetomidine: a novel drug for the treatment of atrial and junctional tachyarrhythmias during the perioperative period for congenital cardiac surgery: a preliminary study. Anesth Analg (2008) 1.64
Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. J Clin Oncol (2010) 1.44
An adaptive, dose-finding, seamless phase 2/3 study of a long-acting glucagon-like peptide-1 analog (dulaglutide): trial design and baseline characteristics. J Diabetes Sci Technol (2012) 1.40
Research issues affecting preoperative systemic therapy for operable breast cancer. J Clin Oncol (2008) 1.18
Pre-counseling education materials for BRCA testing: does tailoring make a difference? Genet Test (2002) 1.04
Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes. Leuk Lymphoma (2010) 1.01
Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res (2002) 1.01
Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial). Breast Cancer Res Treat (2011) 1.00
Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806. Breast Cancer Res Treat (2006) 0.95
Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study. J Clin Oncol (2010) 0.93
Breast cancer heterogeneity may explain peaks in recurrence. Int J Surg (2005) 0.92
Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys (2004) 0.89
Bias and trials stopped early for benefit. JAMA (2010) 0.87
Charting a path toward combination therapy for Alzheimer's disease. Expert Rev Neurother (2014) 0.87
Do neonates, infants and young children need a higher dose of enoxaparin in the cardiac intensive care unit? Cardiol Young (2010) 0.85
Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer. Clin Cancer Res (2002) 0.83
The prognostic implications of macrophages expressing proliferating cell nuclear antigen in breast cancer depend on immune context. PLoS One (2013) 0.80
Building a roadmap for developing combination therapies for Alzheimer's disease. Expert Rev Neurother (2015) 0.80
Bayesian continual reassessment method for dose-finding trials infusing T cells with limited sample size. J Biopharm Stat (2012) 0.79
Dexmedetomidine: promising drug for pediatric sedation? Pediatr Crit Care Med (2005) 0.76
Strategies to improve healthcare websites. AMIA Annu Symp Proc (2006) 0.75
Building a predictive breast cancer risk model. AMIA Annu Symp Proc (2007) 0.75